Avience Biomedicals SME IPO GMP Today

GMP for Avience Biomedicals SME started at Rs 0 on 13 June 2026 and stood at Rs 83 on 23 June 2026. The sharpest single-day jump was from Rs 0 on 14 Jun 2026 to Rs 70 on 15 Jun 2026. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.

Based on today's GMP, Avience Biomedicals SME IPO listing price estimate is Rs 353.00 per share (issue price Rs 208.00 + GMP Rs 145.00).

Actual listing price will be known on 25 June 2026 when the stock lists on NSE/BSE.

A GMP of around 69.7% is a strong positive signal from the grey market. Investors are pricing in a meaningful listing premium over the issue price.

GMP has moved up over the tracked period. Steady increases through the subscription window are usually a stronger signal than a single-day spike.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Avience Biomedicals SME is 385.4x. Compare this with the GMP trend to see if demand aligns. The GMP move around 15 Jun 2026 may reflect how the market reacted once the subscription window activity picked up after 18 Jun 2026.

See live figures on the Avience Biomedicals SME IPO Subscription Status page.

Avience Biomedicals SME IPO full details (financials, peers, review).

Avience Biomedicals Limited, incorporated in June 2024, is an ISO-certified healthcare and biotechnology solutions company. The enterprise specializes in manufacturing, supplying, and exporting high-precision molecular diagnostic formulations, in-vitro diagnostics (IVD) rapid test kits, serology products, and automated biochemistry and hematology analyzers. Operating entirely on business-to-business (B2B) and business-to-government (B2G) frameworks, Avience provides cost-effective diagnostics to premier hospital networks, pathology labs, and research institutions. Its manufacturing footprint is centered in Noida, Uttar Pradesh, with its technical pipelines expanding to cover emergency critical care lines, including oxygen concentrators and viral transport solutions.